covid-19 immunisation programme will be impacted by a subject expert committee deferring its decision on recommending emergency licensure for vaccines by Bharat Biotech International and Serum Institute of India.“We have to be more than reasonably satisfied about safety, immunogenicity and effectiveness (when we give an emergency use authorisation).
It has all been factored in and it will come to a decision soon," NITI Aayog member-health V.K. Paul said at a press conference on Tuesday.Serum Institute of India’s Covishield shots, which is the frontrunner for launch next month, along with Bharat Biotech had applied for an emergency use authorisation for the vaccine to the Drug Controller General of India V.G.